Astra Plots Post-Covid Future With $39 Billion Alexion Deal - msn.com -BoardProspects

Astra Plots Post-Covid Future With $39 Billion Alexion Deal

msn.com Dec 12 2020 BoardNews

(Bloomberg) -- AstraZeneca Plc, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a $39 billion deal for rare-disease specialist Alexion Pharmaceuticals Inc. Load Error The proposed cash-and-stock acquisition will add treatments for uncommon blood and immunological disorders to the portfolio of Cambridge, U.K.-based AstraZeneca, which had spent years paring away older and less profitable ...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- Actavis Is Buying Botox-Maker Allergan for $66B also published in msn.com
- Executive Compensation: What Will 2012 Bring? — The Harvard Law School Forum on Corporate Governance and Financial Regulation also categorized in BoardNews
- Tensions with the Board Not the Norm, Say 98 Percent of CEOs also categorized in BoardNews
- Hewlett-Packard Shakes Up Management, Raises Outlook also mentions Management
- Coca Cola Investor Wants CEO Replaced, Faults Executive Pay also published in msn.com
- Still few women on boards also categorized in BoardNews
- 2011 Annual Corporate Governance Review — The Harvard Law School Forum on Corporate Governance and Financial Regulation also categorized in BoardNews
- Sources: P&G Exploring Sale of $7 Billion Wella Hair Care Unit also published in msn.com
- Boardmember.com's 10 Most Viewed Articles of 2011 also categorized in BoardNews
- Corporate Governance Best Practices also categorized in BoardNews

Search:
Categories
1. BoardProspects Features:
  Board Recruitment Publication, BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
Quotes
1. We believe that in the coming days and weeks the debate about this transaction will center on whether this is enough, and whether other bidders might emerge, rather than whether this was too much.
Topics Mentioned
- Management
- Stock
- COVID
- Bank
- acquisition
- COVID-19
- Bloomberg
- Goldman Sachs
- Morgan Stanley
- JPMorgan
- Bank of America
- Elliott
- JPMorgan Chase
- Pfizer
- Elliott Management
- AstraZeneca
- Eli Lilly
- UK
- Elliott Management Corp.
- Gilead Sciences
- Bank of America Corp
- Pfizer Inc.
- Regeneron
- CFO
- Alexion Pharmaceuticals
- Activist
- Pascal Soriot
- Evercore
- investigation
- earnings
- The Pandemic
- revenue